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Background: Extensively used current guidelines of the American Thoracic Society/European
Respiratory Society (ATS/ERS) define a positive aerosolized bronchodilator (BD) response as:
‘‘.an increase in FEV1 and/or FVC 12% of control and 200 mL.’’ We hypothesized that
BD responsiveness was better assessed using a statistical approach, linked to each individual’s
spirometric measurements, rather than the variability of others.
Design: We retrospectively analyzed 1-year’s pre- and post-BD spirometric tests from our hos-
pital’s clinical laboratory. Using measurements of forced expiratory volume in 1-s (FEV1),
forced expiratory volume in 3-s (FEV3), and forced vital capacity (FVC) from each of three
satisfactory forced pre-BD and three satisfactory forced post-BD spirometric maneuvers, we
classified each of 313 consecutive patient studies as responders or non-responders in two ways.
First, we used ATS/ERS guideline criteria based on population variability. Second, we used
unpaired, single-tailed t-tests at P< 0.05 for FEV1, FEV3, and FVC, considering the variability
of and difference between each individual’s pre- and post-BD maneuvers.
Results: 135 studies were both ATS/ERS and t-test non-responders, three were ATS/ERS
responders and t-test non-responders, 86 were ATS/ERS and t-test responders, and 89 were
ATS/ERS non-responders and t-test responders. The latter 89 included many patients with
either low baseline FEV1 (<1.50 L) who could not reach the 200 mL increase criterion or high
baseline FEV1 (>3.00 L) who could not reach the 12% increase criterion.
Conclusions: We believe individual t-tests may categorize patient’s BD responsiveness better
than ATS/ERS guideline criteria which are based on population responses and require both
fixed volume and percentage changes. Its usefulness by others remains to be shown.
ª 2008 Elsevier Ltd. All rights reserved.of Medicine, Harbor-UCLA Medical Center, Box 405, Torrance, CA 90502, USA. Tel.: þ1 310 222 3803;
.org (J.E. Hansen).
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Table 1 Demographics of study patients and baseline
pulmonary function
Measurement Sample
number
Mean SD Range
Age, years 313a 56.6 11.3 20e90
Height, cm 313 162.6 10.6 142e208
Gender, F/M 183/130
FVC, L 313 2.60 9.6 0.59e6.19
FEV1, L 313 1.73 0.74 0.37e4.59
FEV3, L 313 2.24 0.89 0.52e5.97
FEV1/FVC, % 313 66.4 11.8 28.0e90.7
TLC, L 263 5.01 1.37 2.17e9.84
DLCO, mL/min/mmHg 274 15.6 7.5 1.8e31.4
FVC, forced vital capacity; FEV1, forced expiratory volume in
1-s; FEV3, forced vital volume in 3-s; TLC, total lung capacity;
DLCOZ carbon monoxide transfer factor corrected for
hemoglobin.
a Included were 98 EuropeaneAmericans, 90 LatineAmeri-
cans, 81 AfricaneAmericans, and 44 AsianeAmericans.
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Numerous reports have assessed variability of spirometric
measurements at rest and in response to aerosolized
bronchodilator (BD) in normal subjects and patients.
Evaluees have usually been smokers or non-smokers,1e4
or had asthma or chronic obstructive pulmonary disease
(COPD).3,5e10 Analyses have included: (1) peak flow,
forced expiratory volume in 1-s (FEV1), forced expiratory
volume in 3-s (FEV3), forced vital capacity (FVC), and/or
maximal mid-expiratory flow, singly or in combina-
tion1,2,5,7,8,10e17; (2) volume and percentage change from
baseline and percent change from percent predic-
ted4,6,9,10,13e15; and (3) variability of flow or volumes of
three baseline forced maneuvers followed by changes
from baseline of the best forced maneuver.5e7 These
effects were studied: (a) at rest12,17,18; (b) after placebo
inhalation5,12,15; (c) after a further brief period of rest7;
(d) shortly after aerosolized bronchodilator administra-
tion1,2,4,16; or (e) as variability of maximal maneuvers
over time with durations of a few hours,18,19 weeks,11,15,18
months,17 or several years.10e13
These population responses were subsequently utilized
to establish guidelines for deciding whether an individual
receiving a BD should be reported as a responder or non-
responder. In 1974, the American College of Chest
Physicians suggested that an improvement in two of three
measurements (FEV1, FVC, and maximal mid-expiratory
flow) of 15e25%, 26e50%, or >50% from baseline could
be considered, respectively, as slight, moderate, or
marked reversibility.20 In 1991, the American Thoracic
Society (ATS) guideline stated that ‘‘one should interpret
improvement in an individual subject only if the percent
change and absolute change in FEV1 or VC are clearly
beyond the expected variability of the measurement
during a single testing session.’’21 In 2005, after a detailed
review of many studies, Donohue recommended that an
FEV1 response of 100 mL was the minimally clinically
important difference in COPD.22 That same year, the
American Thoracic Society/European Respiratory Society
(ATS/ERS) guidelines were published, requiring ‘‘an
increase in FEV1 and/or FVC to be 12% of control and
an increase 200 mL to indicate a positive BD
response’’.23 If the above criteria are not met, there is
a ‘‘lack of bronchodilator response’’.23 Meanwhile, others
have noted that fixed arbitrary criteria to evaluate
responsiveness are not appropriate because unimodal
rather than bimodal response patterns were found in
nearly all studies.8,9,22,24
An alternate approach to bronchodilator responsiveness,
which depends only on the findings of each patient, has
twice been reported.24,25 This approach requires calcu-
lating the spirometric variability of each patient and the
statistical difference between pre- and post-BD spirometric
maneuvers.
For this 1-year retrospective study, we compare the
fixed volume and fixed percentage limits of ATS/ERS (A)
guidelines with a statistical method used at Harbor (H)
relying on Student’s t-tests for each patient. These t-tests
use the data ordinarily obtained in clinical laboratories,
e.g. three pre- and three post-forced expiratory maneuversmeeting ATS quality standards. It allows the pulmonary
laboratory to report to the clinician or investigator the
degree (none, minimal, mild, moderate, or marked) and
statistical significance of the response to a BD.
Methods
This retrospective study was approved by our Institutional
Review Board. We reviewed computerized records of all
pulmonary function studies (SensorMedics, Yorba Linda, CA),
all obtained with informed consent, from February 2006,
through January 2007. When post-BD measurements were
ordered, 0.5 mL of undiluted albuterol sulfate inhalation
solution was introduced into a nebulizer connected with an
inlet allowing 7 L/min oxygen flow and an outlet mouth-
piece. Patients were instructed to take a slow deep inhala-
tion from the mouthpiece, breath-hold for 3e5 s, exhale,
relax, and repeat, with or without rinsing the mouth, for
a total of four such inhalations. After a 10 min rest, post-
BD spirometric measurements were started, all recorded
to the closest 0.01 L. Patient diagnoses included asthma,
bronchiectasis, chronic bronchitis, emphysema, heart
failure, infections, interstitial lung disease, malignancies,
obesity, occupational exposure, pulmonary hypertension
and unknowns. We included all patients who had three satis-
factory pre-BD maneuvers and three satisfactory post-BD
maneuvers and met ATS/ERS quality standards.26 These
standards required end-expiratory cessation of flow and
highest two values of FEV1 and FVC (as well as FEV3)
0.15 L apart if FVC 1.5 L or0.10 L apart if FVC 1.0 L.27
Predicted values were calculated for each function measur-
ed.28e31 Patient demographics, spirometric volumes, dura-
tion of each forced expiratory maneuver, and available
concurrent total lung capacity (TLC) and carbon monoxide
transfer factor corrected for hemoglobin (DLCO) measure-
ments were transferred to EXCEL spreadsheets. Demo-
graphics and baseline pulmonary function tests of the 313
suitable patients are shown (Table 1); all variables had
wide ranges.
Criteria for bronchodilator responsiveness 1779Statistical analyses
Each patient that met ATS/ERS criteria23 for responders
(using their largest pre-BD and post-BD FEV1 or FVC values)
was coded as Aþ, each that did not was coded as A. For
the Harbor criteria three pre-BD, FEV1, FEV3, and FVC values
were compared to three post-BD FEV1, FEV3, and FVC values
of each patient by Student’s unpaired one-tailed t-tests at
P< 0.05 level.32 If therewerean individual statistically signif-
icant increase (ISSI) in FEV1 by t-test plus an ISSI by t-tests in
either FEV3 or FVC, the patient was coded as a Harbor
responder (Hþ); if not the study was recorded as a Harbor
non-responder (H). Thus, each patient was coded into one
of four groups: consistent responderZ AþHþ, consistent
non-responderZ AH, or inconsistent responders, either
AHþ or Aþ H. To assess the importance of baseline FEV1
volumes, each group was divided into five subgroups by
0.75 L volume increments.
To assess if training effects during six consecutive
maneuvers were evident, mean SE of FEV1, FEV3, and
FVC for maneuvers 1e6 for each of the above four groups
were calculated. To assess variability of the three baseline
pre-BD FEV1, FEV3, and FVC maneuvers, means, SD’s, SE’s,
coefficients of variation (CV), and 95% confidence intervals
(CI), were calculated for each patient, group, and
subgroup.32 To assess BD effect in each group or subgroup,
changes from three pre-BD to three post-BD values (volume
and percentage from baseline and percentage from pre-
dicted value) were calculated. Correlation coefficients,
slopes, and intercepts were calculated for baseline vari-
ability and changes after BD. Values of P< 0.05 were
considered statistically significant.
To test the practicality of substituting rank order
statistics32 for t-test statistics, we compared the FEV1
changes in all Harbor responders. For example, if all post-
BD trial values exceeded all pre-BD trial values for FEV1,
that study was considered a rank order Harbor responder
for FEV1 at the PZ 0.05 level. If not, any other combina-
tion, including a tie value between pre- and post-BD values,
resulted in a rank order P> 0.05, i.e. a rank order Harbor
non-responder for FEV1.
Results
Responsiveness was consistent in 221 of the 313 patients
(135 were AH and 86 were AþHþ) and inconsistent in 92
patients (89 were AHþ while three were Aþ H). Thus
current ATS/ERS criteria for BD response identified slightly
less than half of the total Hþ responders (86/
[86þ 89]Z 49%). Values of FVC, FEV3, and FEV1 for six
maneuvers, in order, pre- and post-BD, for the four groups
of patients are depicted (Fig. 1). Except for the three
Aþ H studies, there was stability of FEV1, FEV3, and FVC
values for the three pre-BD maneuvers and again for the
three post-BD maneuvers. In the three AþH patients, as
noted in the Fig. 1 legend, the mean FVC and mean expira-
tory times gradually increased over the six maneuvers, but
neither FEV1 nor FEV3 nor FEV6 significantly increased post-
BD (P> 0.05).
The AH, AþHþ and AHþ groups did not differ from
each other in age, gender, % predicted TLC or % predictedDLCO (Table 2). Overall, airway obstruction was worst in
the AþHþ group, intermediate in the AHþ group, and
least in the AH group.
In subgroups with the lowest or highest pre-BD FEV1,
there were many more AHþ patients than AþHþ patients
(Fig. 2). If pre-BD FEV1< 0.75 L, AHþ were 44% vs AþHþ
of 17%; if pre-BD FEV1> 3.00 L, AHþ were 33% vs AþHþ
of 0%. Thus, patients with FEV1< 0.75 L or >3.00 L were
rarely identified as responders by the ATS/ERS guidelines.
Baseline volume variability, as assessed by the SD, of 313
patients increased as baseline FEV1 volumes increased
(Fig. 3A) (P< 0.001 for trend), whereas FVC variability
was not significantly dependent on baseline FEV1. Baseline
percentage variability, as assessed by the CV, for FEV1,
FEV3, and FVC all decreased significantly (P< 0.05,
<0.001, and <0.001 for trend, respectively) as baseline
FEV1 volumes increased (Fig. 3B). Although not illustrated,
as baseline FEV1 increased, the responders’ pre- to post-BD
absolute changes in FEV1 increased (P< 0.001) while
percentage changes decreased in FEV1, FEV3, and FVC (all
P< 0.001). Thus baseline FEV1 volumes affected both base-
line variability and BD responsiveness.
We arbitrarily divided the 175 Hþ responders into four
classes of severity by their post-BD percentage increase in
FEV1 from baseline: 24/175(14%) were minimal, i.e. 2.6e
5.9%; 52/175(30%) were mild, i.e. 6.0e11.9%; 60/175(34%)
were moderate, i.e. 12.0e23.9%, and 19/175(11%) were
marked, i.e. >24.0%.
There was excellent agreement 312/315(99%) between
rank order statistics and one-tailed unpaired Student’s t-
test statistics in evaluating the pre-BD to post-BD changes
in FEV1 (Fig. 4). The three ‘‘disagreements’’ were minimal
and confined to t-test P values of 0.025e0.075. The great
majority of rank tests were concurrent with t-tests P values
which were generally well below or above this narrow
range.Discussion
Our data are not unique. The overall CV of 2e4% for FEV1
and FVC (Fig. 3B) are similar to those referenced in the
ATS/ERS strategy’s Table 8,23 and in other series,1,2,18,24
Several others have described significant individual differ-
ences in natural variability or responsiveness. A marked
decline in CV of FEV1 and FVC as FEV1 increases (Fig. 3B)
was also found by Tweeddale and colleagues7 who found
three to four fold differences in percent variability in
both baseline FEV1 and FVC as group baseline FEV1 values
increased from <1.10 L to >2.45 L. They concluded,
‘‘Natural variability when expressed in percentage terms
was negatively correlated with the level of FEV1
recorded’’.7 The increase in absolute response and
decrease in percentage response as baseline FEV1 increases
is in agreement with the findings of Anthonisen and
colleagues3 who noted, ‘‘Relative response was inversely
proportional to baseline FEV1, whereas absolute response
was directly related to baseline FEV1’’. Data of Herpel
et al.13 from several thousand COPD patients show strik-
ingly higher percent variability of FEV1 and FVC between
sessions in patients who had more severe obstruction. Pen-
nock et al.11 and others also noted higher variability in
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Figure 1 Mean volumes for FVC, FEV3, and FEV1 for consecutive trials pre- and post-BD. (A) Non-responders by American Thoracic
Society/European Respiratory Society (ATS/ERS) criteria and Harbor t-testsZ AH. (B) Responders by ATS/ERS criteria and Harbor
t-testsZ AþHþ. (C) Non-responders by ATS/ERS criteria and responders by Harbor t-testsZ AHþ. (D) AþHZ Responders by
ATS/ERS criteria and non-responders by Harbor t-tests. Note relative stability of mean values pre- and post-BD in all groups but
the AþH group, in which group FVC’s and expiratory times increased post-BD in near parallel fashion. The consecutive mean
AþH expiratory times by trial number were 8.2, 10.6, 11.8, 14.0, 17.6, and 18.8 s. Each of the three AþH studies met ATS/
ERS criteria for BD responsiveness because maximal post-BD FVC increases were greater than 200 mL and 12.0% despite the lack
of similar increases in maximal FEV1, FEV3, or forced expiratory volume in 6-s.
1780 J.E. Hansen et al.patients with airway obstruction. Nickerson et al.24 pointed
out that variability of FEV1 and FVC were approximately
twice as large for cystic fibrosis patients than for normal
subjects and concluded, ‘‘the practice of arbitrarily setTable 2 Group differences and similaritiesa
Group AH AþHþ AHþ
Number 135 86 89
Height, cm 162 11 (a) 166 12 164 11
FEV1, % predicted 70 22 (b) 58 17 (c) 65 22
FVC, % predicted 79 21 (d) 73 18 75 12
FEV1/FVC, % predicted 88 13 (e) 80 15 (f) 86 15
AH, non-responders using American Thoracic Society/Euro-
pean Respiratory Society (ATS/ERS) and Harbor criteria; AþHþ,
responders using ATS/ERS and Harbor criteria; AHþ, non-
responders using ATS/ERS and responders using Harbor criteria.
a Values are mean SD. No significant differences were found
in age, gender, % predicted total lung capacity or % predicted
carbon monoxide transfer factor corrected for hemoglobin.
Significant group differences: (a)Z P< 0.05, AH vs AþHþ;
(b)Z P< 0.001, AH vs Aþ Hþ; (c)Z P< 0.05, Aþ Hþ vs
AHþ; (d)Z P< 0.05, AH vs Aþ Hþ; (e)Z P< 0.001,
AH vs Aþ Hþ; (f)Z P< 0.01, Aþ Hþ vs AHþ.limits at ‘clinically significant’ degrees was not supported
by our data’’. Brand et al.8 in studying patients with
obstructive airways disease concluded that ‘‘response to
a bronchodilator is a continuous variable.and. any cut
off level of a ‘positive’ bronchodilator response is therefore
arbitrary’’.
If cut off levels are arbitrary, how might they have been
derived? The earlier ATS21 and later ATS/ERS23 committees
both referenced two excellent studies.5,7 Each study calcu-
lated the requirement for a single post-BD trial value to
differ by P< 0.05 from the largest baseline spirometric
values by using 2.00 (two-tailed)5 or 1.65 (one-tailed)7 times
the SD of their multiple baseline spirometric trials. Sourk
and Nugent5 before and after placebo inhalations, found
overall mean SD differences (nZ 72) of 11 83 mL and
1.0 5.6% for FEV1 and 25 156 mL and 1.3 6.7% for
FVC. They concluded that the absolute changes necessary
to distinguish the upper confidence limits for significant
BD changes were 178 mL for FEV1 and 340 mL for FVC.
[Note that two-tailed 2.00 83 mL þ11 mL approximates
the 178 mL volume and 2.00 156 mLþ25 mL approximates
the 340 mL volume. Similarly, 2.00 5.6% þ1.0% approxi-
mates 12.3% and 2.00 6.7% þ1.3% approximates 14.9%.]
Tweeddale et al.7 measured variability of three maneuvers
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Criteria for bronchodilator responsiveness 1781of 150 resting subjects and again after 20 min of further rest.
Their average mean SD differences, before and after the
20 min of rest, were: for FEV1, 12 95 mL and
0.7 8.7%; for FVC, 29 198 mL and 1.5 9.0%. They
reported that the 95% confidence limits for significant
volume changes were 160 mL for FEV1 and 330 mL for FVC.
[Note that one-tailed 1.65 95 mlZ 157 mL and
1.65 198 mLZ 327 mL can be rounded to 160 and
330 mL, and 1.65 8.7%Z 14.4% and 1.65 9.0%Z 14.8%
can be rounded to 15%.] Notably, although both studies
used different statistical assumptions, both concluded that
changes after bronchodilator in FEV1 of 160e178 mL and
12e15% and in FVC of 330e340 mL and 14.9e15% were
required to be ‘‘statistically significant’’ from baseline vari-
ability. We argue that although these large 95% confidence
limits for volume and percentage might be appropriate for
statistical significance if only a single post-BD measurement
were considered, these confidence limits are inappropriate
when three satisfactory27 pre-BD and three post-BD
measurements are available for analysis in the clinical or
research laboratory. Apparently both committees21,23
decided against issuing guidelines which required these
high levels for ‘‘statistical significance’’. Rather they chose
‘‘common sense’’ or ‘‘clinically significant’’ values of both
200 mL and 12% for either FEV1 or FVC to define clinical
‘‘responsiveness’’, values considerably different than the
FEV1 100 mL recommended by Donohue as minimally clini-
cally important.
Therefore, we conclude that using fixed population-
based criteria for both FEV1 and FVC for both volume andpercentage change is not optimal, especially since series
differ in drug, dosage and method of administration. The
use of individual variability is statistically sound, logical,
and preferable, because: (1) spirometric values from three
satisfactory pre-BD and three post-BD maneuvers are nearly
always available; (2) the volume (mL) variability of baseline
FEV1 is less than FVC (Fig. 3A) and the mL responses of FEV1
are considerably smaller in responders with low FEV1; (3)
the percentage (CV) of baseline FEV1, FEV3, and FVC all
decrease significantly as baseline FEV1 values increase
(Fig. 3B); (4) in known obstructive airways disease,
responders’ percentage responses decrease strikingly as
baseline values of FEV1 increase; (5) FVC changes may be
predominantly dependent on expiratory times whereas
the FEV1, FEV3, and FEV6 are not (Fig. 1); (6) requiring
a fixed percentage increase to identify ‘‘responsiveness’’
in patients with mild disease tends to exclude some who
may benefit from BD therapy; and, most importantly, (7)
requiring a fixed volume response to identify ‘‘responsive-
ness’’ in patients with severe disease (Fig. 2) tends to
exclude those who may often most need and benefit from
<.
00
01
.
00
1-.
00
01
.
01
-.0
01
.
01
-.0
25
.
02
5-.
05
0
.
05
0-.
07
5
.
07
5-.
10
0
.
10
0-.
20
0
.
20
0-.
50
0
0
10
20
30
40
50
60
70
80
N
u
m
b
e
r
 
o
f
 
R
e
s
p
o
n
d
e
r
s
 
o
r
 
N
o
n
-
r
e
s
p
o
n
d
e
r
s
 
b
y
 
R
a
n
k
 
O
r
d
e
r
 
T
e
s
t
 
@
 
p
=
0
.
0
5
 
p Value of One-tailed t Test for BD Responses
Responders
Non-responders
Figure 4 Comparison of Student’s t-test and rank order
P values of post-BD FEV1 responses of 313 patients, each with
six satisfactory spirometric maneuvers. Rank order P values
are PZ 0.05Z responders or P> 0.05Z non-responders.
Although there is a wide range of unpaired one-tailed t-test P
values, 310/313 (99%) of the comparisons match perfectly; the
other three comparisons have t-test P values between 0.025
and 0.075.
Supplementary data
Supplementary data associated with this article can be
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1782 J.E. Hansen et al.BD therapy. Fortunately, as shown, fixed criteria can be
avoided and true statistical significance determined with
an approach which utilizes all six satisfactory measure-
ments from pre-BD and post-BD trials. It would be useful
to ascertain if one could reduce changes in reversibility
status in prior series10 by substituting Harbor statistical
criteria for fixed criteria.
To quantify, for the clinician, the percentage change of
the post-BD FEV1 from baseline, terms like minimal for
<6%, mild for 6e12%, moderate for 12e24%, and marked
for >24% might be reasonable. However, responsiveness
should not be used as the sole criterion for separating
asthma from COPD.8,12
If easily available, Student’s t-tests are optimal, but rank
order tests are remarkably simple and useful.9 If all three of
the post-BD FEV1 trials are higher than all three of the pre-BD
FEV1 trials, the rank order change is significant at the
PZ 0.05 level. In our study only 3 of 313 FEV1 rank order
statistics at the PZ 0.05 level disagreed with the one-tailed
unpaired t-test statistic at the P< 0.05 level; these 3 all had
t-test values between PZ 0.025e0.075.
This was not a study of a population selected for
presence or absence of disease or exposure to smoking. It
has been suggested that we should have used two-tailed or
paired t-tests. Because we were testing for improvement
rather than decline following aerosolized BD, a one-tailed
t-test seems appropriate, just as a one-tailed test (1.65
times SD) is normally used to identify obstruction or restric-
tion. Because maneuvers 1, 2, and 3 should be compared to
maneuvers 4, 5, and 6 rather than comparing 1e4, 2e5, and
3e6, unpaired tests are preferable. The 99% agreement of
unpaired one-tailed t-tests to rank order tests is
confirmatory.Prior findings that small BD responses occur in up to 10%
of populations considered to be normal does not detract
from the fact that such responses can be beneficial to
patients with symptomatic airway obstruction. Further-
more, there is no disadvantage to statistically analyzing
the three satisfactory pre- and post-BD trials and reporting
to the referring clinician the degree of consistency and
change of the spirometric measures. Because current
guidelines for bronchodilator response lessen the impor-
tance of the individual patient’s spirometric consistency,
and require both fixed percentage and fixed volume
increases, the alternate approach suggested here should
enhance information transfer to clinicians with respect to
the responsiveness of their patients to bronchodilators.
There may also be a significant reduction in the variability
of bronchodilator responsiveness in patients with obstruc-
tive airways disease if statistical rather than fixed criteria
were used in past and future clinical trials.Acknowledgement
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